Aesica appoints Ian Muir to the newly created position of commercial managing director.
Aesica
, a CDMO, has appointed Ian Muir to the newly created position of commercial managing director, effective on February 24. Muir’s responsibilities will cross all three of the company’s service offerings in API manufacturing, formulation development, and formulated products. He will also lead the expansion of the business into new markets, including China and Japan. Muir will report directly to Robert Hardy, CEO, and will be joining the Aesica Board.
Previously, Muir worked at Catalent where he was responsible for the global provision of contract development and manufacturing services for oral dose forms. He also has commercial experience in contract manufacturing roles for pharmaceutical companies located in Europe, the US, and Australia.
Source:
Aesica
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.